COMMUNIQUÉS West-GlobeNewswire

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
17/02/2026
PharmaPack Program to Expand Access to Affordable, FDA-Approved Branded Ophthalmic Therapies NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management [...]
AMT Medical Appoints Geert van Gansewinkel as CEO to Lead Company into Next Growth Phase Revolutionizing Coronary Artery Bypass Surgery
17/02/2026
www.amt-medical.nl https://vimeo.com/636954313 Anticipated Clinical Results on Graft Durability and Minimally Invasive Applications to Shape Company’s Future EDE/UTRECHT, The Netherlands – February 17, 2026 – AMT [...]
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
17/02/2026
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, [...]
Oculis Appoints Katie Kazem as Chief Legal Officer
17/02/2026
ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to [...]
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
17/02/2026
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]
Communiqué de presse : Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn
17/02/2026
Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Dans l’étude de phase IIb [...]
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
17/02/2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
17/02/2026
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced [...]
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
17/02/2026
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety [...]
Oculis Appoints Katie Kazem as Chief Legal Officer
17/02/2026
Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companies Chief Legal Officer (CLO) [...]
Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
17/02/2026
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global [...]
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
17/02/2026
$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17/02/2026
WATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
17/02/2026
ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial [...]
RadNet, Inc. Announces Date of its Fourth Quarter 2025 Financial Results Conference Call
17/02/2026
LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
17/02/2026
Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD HEIDELBERG, Germany, Feb. 17, 2026 (GLOBE NEWSWIRE) -- FundaMental Pharma [...]
Change to the Roche Enlarged Corporate Executive Committee
17/02/2026
Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research and Early Development (pRED), effective 1 May 2026. [...]
Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
17/02/2026
Leiden, the Netherlands, February 17, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer 36 th Annual Healthcare Life [...]
Inventiva publie ses résultats financiers préliminaires pour l’exercice 2025¹
17/02/2026
Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme 2 au 31 décembre 2025 Chiffre d’affaires de 4,5 millions d’euros en 2025 Réalisation d’une offre au [...]

Pages